clinical trial · NCT04516967
Avatrombopag for the Treatment of Thrombocytopenia in Pediatric Subjects With Immune Thrombocytopenia for ≥6 Months
Sobi, Inc.·phase3·completed·n = 75
Immune ThrombocytopeniaAvatrombopagPlacebo
brief summary
A Phase 3b Study to Evaluate the Efficacy and Safety of Avatrombopag for the Treatment of Thrombocytopenia in Pediatric Subjects with Immune Thrombocytopenia for ≥6 Months
started
Mar 5, 2021
primary completion
Nov 8, 2023
completion
Oct 28, 2025
last updated
Apr 22, 2026
detailed description
Subjects will be randomized in to blinded therapy of avatrombopag or placebo in a 3:1 ratio for a period of 12 weeks. Subjects who complete the 12 week treatment period and are eligible may continue to the open label extension phase which will last 2 years.
official title
Randomized, Double-blind, Placebo-controlled Study With Open-label Extension Phase to Evaluate the Efficacy and Safety of Avatrombopag for the Treatment of Thrombocytopenia in Pediatric Subjects With Immune Thrombocytopenia for ≥6 Months
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol